Shukra Pharmaceuticals Ratios

Shukra Pharmaceuticals Ltd Ratios

The Shukra Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Shukra Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Shukra Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Shukra Pharmaceuticals Ltd (NSE: , BSE: 524632) is currently trading at ₹42.09, with a market capitalization of ₹18.65B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Shukra Pharmaceuticals Ltd remains a key stock for fundamental analysis using Shukra Pharmaceuticals Ltd Ratios.

Shukra Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Shukra Pharmaceuticals Ltd P/E ratio currently stands at 99.91, making it one of the most tracked metrics in Shukra Pharmaceuticals Ltd Ratios.

Historically, the Shukra Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 99.91
• 2023: 19.29
• 2022: 1.79
• 2021: 12.62
• 2020: 37.35

The rising Shukra Pharmaceuticals Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Shukra Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 15.23.

Historical P/B trend:

• 2024: 15.23
• 2023: 6.20
• 2022: 2.03
• 2021: 0.58

Shukra Pharmaceuticals Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Shukra Pharmaceuticals Ltd P/S ratio currently stands at 29.36, an important part of Shukra Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 29.36
• 2023: 4.79
• 2022: 0.13
• 2021: 0.46

The rising Shukra Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.

Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 108.69.

Historical Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 108.69
• 2023: 0
• 2022: 2.65
• 2021: 1.26
• 2020: 11.93

The rising Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Shukra Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Shukra Pharmaceuticals Ltd EV currently stands at ₹9.49B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 9.49B
• 2023: 3.51B
• 2022: 89.97M
• 2021: 127.5M

Shukra Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Shukra Pharmaceuticals Ltd EV/EBITDA ratio is currently 74.44, a key metric in Shukra Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 74.44
• 2023: 18.03
• 2022: 1.39
• 2021: 4.40

Higher Shukra Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.

Shukra Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Shukra Pharmaceuticals Ltd D/E ratio is currently 0.07, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.07
• 2023: 0.05
• 2022: 0.20
• 2021: 0.21

Shukra Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Shukra Pharmaceuticals Ltd ROE currently stands at 15.90%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 15.90
• 2023: 44.70
• 2022: 21.16
• 2021: 4.70

Shukra Pharmaceuticals Ltd maintains stable profitability levels.

Shukra Pharmaceuticals Ltd Ratios Analysis Summary

The Shukra Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Shukra Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Shukra Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.